Skip to main content
Fig. 7 | Health Economics Review

Fig. 7

From: Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study

Fig. 7

Cost-effectiveness acceptability curves from probabilistic sensitivity analysis. A. Primary Analysis, All Treatments; B. Primary Analysis, Excluding BSC; C. Scenario Analysis, Excluding Asian Trials, All Treatments; D. Scenario Analysis, Excluding Asian Trials, Excluding BSC. BSC, Best Supportive Care; REDo, regorafenib dose optimization; TAS-102, trifluridine/tipiracil; TAS-BEV, TAS-102 with bevacizumab

Back to article page

Health Economics Review

ISSN: 2191-1991

Contact us